New drug combo aims to shrink Hard-to-Treat throat cancer

NCT ID NCT07388758

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two drugs—scipibaimab and tislelizumab—can shrink tumors in people with recurrent or metastatic nasopharyngeal carcinoma that has worsened after first-line treatment. About 37 adults whose cancer has not responded to platinum chemotherapy and a PD-1 inhibitor will receive the combination. The main goal is to see how many patients have their tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: scipibaimab (a lab-made antibody) and tislelizumab (an immunotherapy drug)
What this could lead to: If it works, this combination could offer a new treatment option for people with advanced nasopharyngeal cancer that has stopped responding to standard therapy.
What could go wrong: This is a small, early-phase trial with only 37 people, so results may not apply to everyone. The drugs can cause immune-related side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

Contacts and locations

Locations

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.